---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Kidney transplantation"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Kidney transplantation. Topics: Preemptive transplantation: KDIGO 2024 CKD guideline, Transplant access for Black people with kidney failure in the United States, Allograft survival of kidneys from deceased donors with two APOL1 risk variants, Allograft survival by recipient APOL1 genotype, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/kidney-transplantation"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Kidney transplantation

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Kidney Transplantation

<a id="topic-2.2.2.1.8-1"></a>

### Preemptive transplantation: KDIGO 2024 CKD guideline

> “Practice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15–20 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.”
> “Practice Point 5.4.5: Pursue living or deceased donor preemptive kidney transplantation as the treatment of choice for children in whom there is evidence of progressive and irreversible CKD.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.8-2"></a>

### Transplant access for Black people with kidney failure in the United States

> “The rate of deceased donor kidney transplant among Black people with ESRD consistently exceeded that of White people after implementation of changes to the kidney allocation system in 2021 (KAS250) (Figure 7.1b).”
> “Rates of living donor kidney transplant remained about four times higher among White as among Black people with ESRD and about twice as high among White as among Hispanic people in 2024 (Figure 7.1b).”

Source: [USRDS Annual Data Report, kidney transplant (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/7-kidney-transplant)

<a id="topic-2.2.2.1.8-3"></a>

### Allograft survival of kidneys from deceased donors with two APOL1 risk variants

> “Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.”
> “A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.”

Source: [Freedman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684443/)

<a id="topic-2.2.2.1.8-4"></a>

### Allograft survival by recipient APOL1 genotype

> “Recipients carrying two APOL1 RA demonstrated lower graft survival compared to recipients with only one or none of APOL1 RA at 1-year posttransplant independently of other donor and recipient characteristics (Adjusted HR 3.2 [95% CI 1.0–10.4, p-value 0.05]). There was no significant difference in overall survival or graft survival after 3 years posttransplantation.”

Source: [Roy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11184510/)

<a id="topic-2.2.2.1.8-5"></a>

### Kidney function after living donation by APOL1 genotype: APOLLO

> “Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2).”
> “Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

<a id="topic-2.2.2.1.8-6"></a>

### FSGS recurrence and donor APOL1 testing: KDIGO 2021 glomerular diseases guideline

> “In contrast, it is widely accepted that the recurrence rate of FSGS after transplantation is significantly low in genetic forms of the disease, with some studies reporting no individuals exhibiting recurrent disease after a kidney transplant.”
> “Furthermore, it has also been shown that APOL1 high-risk donor kidneys fail at higher rates than non-risk kidneys, and the recipient APOL1 genotype has not been demonstrated to”
> “have correlation with allograft survival.”
> “Therefore, in donors at high risk for APOL1 risk variants, genetic testing for APOL1 mutations may provide information for both the disease risk in the donor and allograft outcomes in the recipient.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.8-7"></a>

### Implications for kidney transplantation: KDIGO 2025 APOL1 conference report

> “In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation”
> “but recipients with high-risk APOL1 genotypes may also have reduced graft survival.”
> “Agents must be shown to be safe in the transplant setting, including lack of interaction with immunosuppressive agents.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.1.8-8"></a>

### Monitoring for recurrent HIVAN after transplantation

> “Given the strong association between the APOL1 risk variants and HIVAN, HIV-positive recipients of African descent and those who receive an allograft from a donor of African descent should be monitored for recurrent HIVAN.”

Source: [Swanepoel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983378/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
